

Guidelines developed for diabetes management in CKD

November 18 2020



(HealthDay)—In a synopsis of the 2020 Kidney Disease: Improving

Global Outcomes (KDIGO) clinical practice guideline, published online Nov. 10 in the *Annals of Internal Medicine*, recommendations and practice points are presented for clinicians caring for patients with diabetes and chronic kidney disease (CKD).

Sankar D. Navaneethan, M.D., from the Baylor College of Medicine in Houston, and colleagues provide a summary of the KDIGO guidelines for diabetes management in CKD.

The guidelines include 12 recommendations and 48 practice points for clinicians, and relate to comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and education and integrated care approaches. For patients with diabetes, hypertension, and albuminuria, treatment with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker should be initiated. Patients with diabetes and CKD who use [tobacco products](#) should be advised to quit. Hemoglobin A1c should be used to monitor glycemic control, and individualized targets are recommended, ranging from

Citation: Guidelines developed for diabetes management in CKD (2020, November 18) retrieved 6 May 2024 from <https://medicalxpress.com/news/2020-11-guidelines-diabetes-ckd.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--